Tải bản đầy đủ - 68 (trang)
CHƯƠNG 5. KẾT LUẬN VÀ ĐỀ NGHỊ

CHƯƠNG 5. KẾT LUẬN VÀ ĐỀ NGHỊ

Tải bản đầy đủ - 68trang

TÀI LIỆU THAM KHẢO

Tài liệu tiếng Việt



1. Bộ môn dược liệu (2012), Giáo trình phương pháp nghiên cứu dược liệu, Đại

học Y Dược Tp.Hồ Chí Minh, tr.72-84 .



2. Châu Ngọc Hoa (2012), Bệnh học nội khoa, NXB Y Học, TP. HCM, tr.68-80.

3. Mai Phương Mai (2012), Dược Lý Học, NXB Y Học, Hà Nội, tr.47-53.

4. Phạm Khánh Phong Lan (2007), Các phương pháp quang phổ xác định cấu trúc

hợp chất hữu cơ 2, Đại học Y Dược TPHCM, tr.9-60.



5. Võ Thị Bạch Huệ, Vĩnh Định (2008), Hóa phân tích 2, Nhà xuất bản Y học,

tr.106-119.

Tài liệu nước ngoài

Sách



6. G.K. McEvoy (2011), AHFS Drug Information Essentials, American Society of

Health-System Pharmacists, Inc., Maryland.



7. R. Ramanathan (2009), Mass Spectrometry in Drug Metabolism and

Pharmacokinetics, A Jonh Wiley & Sons, INC., p.12.



8. S. Budavari, M.J. O’Neil, A. Smith, P.E. Heckelman (1989), The Merck index,

Merck & CO., MỸ

Tạp chí



9. Al. Williamson (1851), “Ueber die Theorie der Aetherbildung”, A. Ann. Chem.

Pharm., 77(1), 37-49.



10.



Alexander W. Williamson, Ph.D. F.C.S (1852), “XXII.-On etherification”, J.



Chem. Soc., 4(3), 229-239.



11.



M.C. Allely, B.J. Alps (1990), “Prevention of myocardial enzyme release by



Ranolazin in a primate model of ischaemia with reperfusion”, Br J Pharmacol.,

99(1), 5–6.



12.



B. Bhandari, L. Subramanian (2007), “Ranolazin, a partial fatty acid



oxidation inhibitor, its potential benefit in angina and other cardiovascular

disorders”, Recent Pat Cardiovasc Drug Discov., 2(1), 35-39.



13.



B.M. Reddly, H.S. Weintraub, A.Z. Schwartzbard (2010), “Ranolazin A New



Approach to Treating an Old Problem”, Texas Heart Institute Journal, 37(6),

641-647.

14. B.R. Kim et al (2012), “tert-Butoxide-Assisted Amidation of Esters under Green

Conditions”, Synthesis 2012, 44(1), 42-45



15.



C.E.R. Agiai, T.K. Gizur, K.F. Harsan Yi, F.U. Trischler, S.A.A. Dermether,



A.L. Csehi, E.S. Vijda and G.A. Szab-komi si (1991), “Process For The

Preperation Of Piperazin Derivatives”, Eur. Pat, EP 0483932 A1.



16.



B.R.



Chaitman, C.J.



Pepine, J.O.



Parker, J.



Skopal, G.



Chumakova,



J. Kuch, W. Wang, SL. Skettino, A.A. Wolff (2004), “Effects of Ranolazin with

atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in

patients with severe chronic angina: a randomized controlled trial”, JAMA,

291(3), 309-316.



17.



B.R. Chaitman (2004), “Efficacy and safety of a metabolic modulator drug in



chronic stable angina: review of evidence from clinical trials”, J. Cardiovasc

Pharmacol Ther., 9(1), 47–64.



18.



D. Chunyun, Z. Yi Hong, El.H. Aziza et al (2014), “Ranolazin inhibition of



hERG potassium channels: Drug–pore 3 interactions and reduced potency

against inactivation mutants”, J Mol Cell Cardiol.,74(1), 220-230.



19. D.N. Kommi, D. Kumar and A.K. Chakraborti (2013), “ “All water chemistry”

for a concise total synthesis of the novel class anti-anginal drug (RS), (R), and

(S)-ranolazine”, Green Chem., 15(1), 756–767.



20.



K. Fox, M.A. Garcia, D. Ardissino et al (2006), “Guidelines on the



management of stable angina pectoris: executive summary: The Task Force on

the Management of Stable Angina Pectoris of the European Society of

Cardiology”, Eur Heart J., 27(11), 1341–1381.



21.



G.A. Youngdale, G.W. Duncan, D.E. Emmert, D. Lednicer (1966),



“Synthesis



and



Antifertility



Activity



of



5-(Phenoxymethpl)-2-



oxazolidinethiones”, J. Med. Chem., 9(1), 155-157.



22.



H. Hyosook, M.A. Joseph, L.H. Sharon, Z.S. Boris et al (2009), “Ranolazin



as an Adjunct to Cardioplegia: A Potential New Therapeutic Application”, J

Cardiovasc Pharmacol Ther., 14(2), 125-133.



23.



K. Audouze, E.S Nielsen and D. Pethers (2004), “New Series of Morpholine



and 1,4-Oxazepane Derivatives as Dopamine D4 Receptor Ligands: Synthesis

and 3D-QSAR Model”, Journal of Medicinal Chemistry, 47(12), 3089-3104.



24.



Kluge



et



al



(1986),



“Cardioselect



Ive



Aryloxy-



And



Arylthio



Hydroxypropylene-Piperazinyl Acetanilides Which Affect Calcium Entry”, U.S

Pat. No. 4,567,264.



25.



L.R. Madivada, R.R. Anumala, G.Gilla, M.Kagga and R. Bandichhor (2012),



“An Efficient Synthesis of 1-(2-methoxyphenoxy)-2,3-epoxypropan: Key

Intermediate of β-Adrenoblockers”, Org. Process Res. Dev., 16(10), 1660-1664.



26.



M. Aldakkak, D.F. Stowel and A.K.S Camara (2013), “Safety and Efficacy of



Ranolazin for the Treatment of Chronic Angina Pectoris”, Clin Med Insight

Ther., 2013(5), 1-14.



27.



P. Lamendola et al (2013), “Effect of Ranolazin on arterial endothelial



function in patients with type 2 diabetes mellitus”, Atherosclerosis, 226(1), 157160.



28.



P.B Deshpande, A.D. Chauhan (2006), “Crystalline and amorphous form of



Ranolazin and process for manufacturing them”, PCT Int Pat, WO 2006008753

A1.



29.



R.M. Anders, K. Rasmus and A. Thorleif (2005), “Chemo-enzymatic



synthesis of both enantiomers of the anti-anginal drug Ranolazin”, Biocatalysis

and Biotransformation, 23(1), 45-51.



30.



V.L. Roger, A.S. Go, D.M. Lloyd-Jones et al. (2012), “Executive summary:



heart disease and stroke statistics-2012 update: a report from the American Heart

Association”, Circulation, 125(1), 188-97.



31.



S. Aalla, G. Gilla, R.R. Anumula et al (2012), “Improved Process For



Ranolazin: An Antianginal Agent”, Org. Process Res. Dev., 16(5), 748-754.



32.



T. Ohshima, Y. Hayashi, K. Agura, Y. Fujii, A. Yoshiyama and K. Mashima



(2012), “Sodium methoxide: a simple but highly efficient catalyst for the direct

amidation of ester”, Chemical Communication, 44(1), 5434-5436.



33.



A.D. Timmis, B.R. Chaitman and M. Crager (2006), “Effects of Ranolazin



on exercise tolerance and HbA1c in patients with chronic angina and diabetes”,

Eur Heart J, 27( 1), 42–48.



34.



Yao, Zhangyu, Gong, Shubo, Guan, Teng, Li, Yunman, Wu, Xiaoming, Sun,



Hongbin (2009), “Synthesis of Ranolazin Metabolites and Their Antimyocardial Ischemia Activities”, Chemical and Pharmaceutical Bulletin,

57(11), 1218-1222.



PHỤ LỤC



hụ lục 4.1 Phổ IR của 1-2(methoxyphenoxy)-2,3-epoxypropan (RO-1)



hụ lục 4.2 Phổ 1H-NMR của 1-(2-methoxyphenoxy)-2,3-epoxypropan (RO-1)



hụ lục 4.3 Phổ 1H-NMR mở rộng của 1-(2-methoxyphenoxy)-2,3-epoxypropan (RO-1)



hụ lục 4.4 Phổ 1H-NMR của 1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]piperazin (RO-2)



hụ lục 4.5 Phổ 1H-NMR mở rộng của 1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]piperazin (RO-2)



Tài liệu bạn tìm kiếm đã sẵn sàng tải về

CHƯƠNG 5. KẾT LUẬN VÀ ĐỀ NGHỊ

Tải bản đầy đủ ngay(68 tr)

×